Multiple system atrophy is a type of neurodegenerative disorder that affects movement of the body and the autonomic nervous system which leads to loss of function and death of the nerve cells in spinal cord and brain. Multiple system atrophy can be symptomatized by erectile dysfunction, bladder control and fainting spells. Due to motor nervous system impairment, difficulties with speech and gait, along with tremor and rigidity occurs. However, the cause of the disease is still unknown, but it has been observed that the accumulation of alpha synuclein causes the degradation of nerve cells in the brain and spinal cord. The University Hospital, Toulouse is in the process of developing L-Threo DOPS as a synthetic precursor of norepinephrine, for the treatment of multiple system atrophy. The Vanderbilt University is in the process of developing BQ-123 as an endothelin receptor (ETA) antagonist for the treatment of multiple system atrophy. Some of the universities and companies having the pipeline of multiple system atrophy include Vanderbilt University, New York University School of Medicine, CORESTEM, Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.